20-Sep-2022 | Facts and Factors
According to Facts and Factors, the global endoscopic retrograde cholangiopancreatography (ERCP) market size was worth around USD 1.4 billion in 2021 and is predicted to grow to around USD 2.5 billion by 2028 with a compound annual growth rate (CAGR) of roughly 8.5% between 2022 and 2028.
The ERCP procedure, also known as endoscopic retrograde cholangiopancreatography, is used to identify and address issues with the pancreas, liver, gallbladder, and bile ducts. It combines the use of an endoscope—a long, flexible, lighted tube—with X-ray technology.
Browse the full “Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size, Share, Growth Analysis Report By Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, and Others), By Application (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, and Pancreatic Duct Dilatation), By End-User (Hospitals & Clinics, Ambulatory Surgery Centers and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/endoscopic-retrograde-cholangiopancreatography-ercp-market
The high prevalence of chronic disorders like Crohn's disease, Barrett's disease, and pancreatic cancer around the world, together with government measures to raise patient knowledge of better and more cutting-edge therapies, are driving the global endoscopic retrograde cholangiopancreatography (ERCP) market's expansion. However, the strict government regulations imposed by regulatory organizations in many countries for the introduction of new technologies are limiting the market's expansion. The market is benefiting from the rising disposable income, particularly in developing nations where consumers are becoming more aware of cutting-edge technology. The high expense of the treatment could be a barrier to the market's expansion.
Global endoscopic services have been significantly impacted by the COVID-19 outbreak. The virus can also spread by contact and droplets. Since the disease spreads mostly through direct contact or aerosol droplets and endoscopic procedures demand a close physical distance between patients and medical workers, endoscopy practitioners are therefore at significant risk during the pandemic. The volume of ERCP cases decreased by 44.1% from March 2020 to April 2020 compared to the corresponding 2019 timeframe, according to a study titled "A Multicenter Survey on Endoscopic Retrograde Cholangiopancreatography During the COVID-19 Pandemic in Northern and Central Italy" published in April 2021. The case-volume drop for ERCP during lockdown was, however, reported in the same study to be less than for other gastrointestinal endoscopic procedures. COVID-19 thus had a substantial impact on the endoscopic retrograde cholangiopancreatography market.
The global endoscopic retrograde cholangiopancreatography (ERCP) market is segmented based on product, application, end-user, and region.
The global market is divided into endoscopes, endotherapy devices, visualization systems, energy devices, and others based on the product. The market's largest contributor, the endoscopes segment, is expected to expand at a CAGR of 8.9% during the projected period. The market for endoscopic retrograde cholangiopancreatography devices for endoscopes is anticipated to grow significantly over the next few years as a result of an increase in gastrointestinal and chronic biliary problems. The World Health Organization estimates that gastrointestinal (GI) illnesses are responsible for about 8 million deaths each year. As a result, it is projected that there would be a rise in conditions linked to pancreatic cancer and the bile duct liver. Additionally, it opens up a huge window of opportunity for producers of endoscopic retrograde cholangiopancreatography devices to grow their brands internationally. In the upcoming years, it is also projected that rising health care costs and advantageous administrative rules will spur market expansion.
The global market is bifurcated into biliary sphincterotomy, biliary stenting, biliary dilatation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation based on application. The market's largest contributor, biliary sphincterotomy, expanded at a CAGR of 8.1% over the projection period. After selective cannulation with a specialized tool called a sphincterotome introduced into the papilla, the biliary sphincter and the intraduodenal portion of the common bile duct are severed using a high-frequency current. Biliary sphincterotomy or biliary endoscopic sphincterotomy are the names of this surgery (EST).
Based on the end user, the global market is divided into hospitals & clinics, ambulatory surgery centers, and others. The market's largest contributor, the hospitals and clinics sector, is expected to rise at a CAGR of 7.8% during the projected period. Ambulatory surgery centers, or ASCs, are specialized medical facilities that give patients the choice to have surgeries and other treatments performed outside of a conventional hospital setting. Due to the high prevalence of pancreatic cancer, bile duct, and pancreatic duct illnesses, the segment for ambulatory surgical centers is anticipated to experience the highest growth during the projection period. These aspects are anticipated to encourage the ERCP market.
In 2021, the global endoscopic retrograde cholangiopancreatography market in North America held the highest share, accounting for 35% of the global market. This region is expanding as a result of intensive diagnostic imaging research and the rapid introduction of technologically advanced ERCP tools like sphincterotomes. The expansion of the endoscopic retrograde cholangiopancreatography market in the North American area is further fueled by the increase in government funding for healthcare and the presence of major players like Hobbs Medical Inc. Furthermore, it is predicted that over the projected period, the Asia-Pacific region will experience the fastest CAGR rate. The healthcare industry's development is a contributing factor to this rise. The development of the Endoscopic Retrograde Cholangiopancreatography Market in the Asia-Pacific region is further fueled by the rising awareness regarding the treatment of pancreatic and liver disorders involving sphincterotomy.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 1.4 Billion |
Projected Market Size in 2028 |
USD 2.5 Billion |
CAGR Growth Rate |
8.5% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Olympus Corporation, CONMED Corporation, HOYA Corporation, Fujifilm Holdings Corporation, KARL STORZ SE & Co. KG, Ambu A/S, Johnson & Johnson, Boston Scientific Corporation, Medtronic, PLC, Cook Medical, B. Braun Melsungen AG, and others. |
Key Segment |
By Product, Application, End User, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The global endoscopic retrograde cholangiopancreatography (ERCP) market is dominated by players like Olympus Corporation, CONMED Corporation, HOYA Corporation, Fujifilm Holdings Corporation, KARL STORZ SE & Co. KG, Ambu A/S, Johnson & Johnson, Boston Scientific Corporation, Medtronic, PLC, Cook Medical, and B. Braun Melsungen AG, among others.
Recent Development:
- In January 2022, Cook Medical launched an endoscopic clipping device, namely Instinct Plus, which is compatible with a duodenoscope and has applications for defect closure, anchoring procedures, and prophylactic clipping in the gastrointestinal (GI) tract.
The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market is segmented as follows:
By Product
- Endoscopes
- Endotherapy Devices
- Visualization Systems
- Energy Devices
- Others
By Application
- Biliary Sphincterotomy
- Biliary Stenting
- Biliary Dilatation
- Pancreatic Sphincterotomy
- Pancreatic Duct Stenting
- Pancreatic Duct Dilatation
By End User
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
